RO5095932

Hoffmann-La Roche · Phase 1 active Small molecule

At a glance

Generic name	RO5095932
Sponsor	Hoffmann-La Roche
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus (PHASE1)
A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RO5095932 CI brief — competitive landscape report
RO5095932 updates RSS · CI watch RSS
Hoffmann-La Roche portfolio CI